Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study.

Chuchalin, Alexander G, Tsoi, Alla N, Richter, Kai, Krug, Norbert, Dahl, Ronald, Luursema, P B, Cameron, Ray, Bao, Weibin, Higgins, Mark, Woessner, Ralph and van As, Andre (2007) Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study. Respiratory Medicine, 101 (10). pp. 2065-2075. ISSN 0954-6111


The safety and tolerability of indacaterol, a novel once-daily beta(2)-agonist bronchodilator with a fast onset of action, were assessed in 156 asthma patients in a multicentre, randomized, double-blind, placebo-controlled study. Patients received indacaterol 200, 400 or 600 microg or placebo once daily for 28 days. Adverse events (AEs), laboratory assessments, vital signs, electrocardiograms, spirometry and physical examinations were monitored. Indacaterol pharmacokinetics were assessed. There was no evidence of dose-related increases in AE incidence or clinically significant hypokalaemia or hyperglycaemia in indacaterol-treated patients. Mean pulse rate changes were minor in any group, with maximum 1-h post-dose changes from baseline of -3.7, -3.3 and -2.2 bpm for indacaterol 200, 400 and 600 microg, respectively, and -2.9 bpm for placebo. Mean QTc interval was similar between groups; change from baseline >60 ms occurred in only two patients. Mean FEV(1) increased after the first indacaterol dose; baseline-adjusted pre-dose (trough) values remained >or=166 mL higher than placebo at all subsequent visits, supporting a 24-h bronchodilator effect. Pre-dose (but not post-dose) serum indacaterol concentrations indicated a slight trend for accumulation. Once-daily indacaterol 200-600 microg has a favourable therapeutic index. It is well tolerated, and is not associated with any adverse cardiac or metabolic effects, while providing effective 24-h bronchodilation.

Item Type: Article
Related URLs:
Additional Information: author can archive post-print (ie final draft post-refereeing); Publisher's version/PDF cannot be used
Related URLs:
Date Deposited: 09 May 2011 23:45
Last Modified: 01 Feb 2013 00:47


Email Alerts

Register with OAK to receive email alerts for saved searches.